Australia-based oro-mucosal drug delivery company, SUDA Pharmaceuticals (ASX:SUD) notified in its latest update that the Japanese Patent Office has accepted its patent application for Anagrelide. Consequently, the Anagrelide Cancer Patent will proceed to grant.
Below are the key details of the patent:
- Application No.: 2017-534600
- Title: Use of Anagrelide for Treating Cancer
- Expiry date: December 2035
Anagrelide is an EMA and FDA approved drug to treat blood disorders and recent research has continued to support the rationale for its use in treating cancer. Notably, SUDA is the only firm across the world holding patents covering the use of anagrelide in treating or preventing metastatic disease in the bone or lung.
Post the update, SUD stock surged by ~10.3 per cent, trading at $0.043 as at 12:15 PM AEST on 20 May 2020.